Stem cell research hits the French political agenda
This article was originally published in Clinica
Embyronic stem cell research has risen to the top of the French political agenda, one month after both Houses of the UK Parliament voted in favour of using this ethically sensitive technique (see Clinica No 943, p 5). But with a presidential election next year, the French politicians are treating the delicate subject with extreme caution. As the President, Jacques Chirac, and the Prime Minister, Lionel Jospin, represent opposing views, the parliamentary debate could be long and slow.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.